Healthcare company Uniphar has today announced a deal to buy Dutch firm BModesto Group for a total consideration of €75m.
BModesto, a healthcare services business focused on improving access to pharmaceutical and healthcare products across the Netherlands, Germany, the UK and Europe, reported EBITDA of €7.7m in 2021.
The company offers services including the distribution of medicines on both an exclusive and on-demand basis, clinical trial services, market authorisation holder and medical device distribution.
It has a workforce of more than 180 people and since its foundation in 2014, it built up a strong international sourcing network to gain access to these much needed and often difficult to source medicines.
Uniphar said that BModesto will be integrated into its Product Access division and will support the delivery of existing services into the strategically important European market.

Uniphar said the purchase price includes an upfront payment of €51m, which will be funded from existing banking facilities.
It also includes a deferred consideration payment of up to €24m contingent upon the achievement of EBITDA and Gross Profit based performance targets.
Ger Rabbette, CEO of Uniphar said, said that BModesto is a significant addition to the group, strengthening its Product Access offering in Europe and beyond.

“The acquisition is another step in achieving our strategy of becoming a global leader in the ethical provision of access to medicines which remain unlicensed at the point of care. It also provides a further boost to our capabilities in the provision of Expanded Access Programs for innovative new medicines,” he said.
“The company’s strategic location, sophisticated sourcing, regulatory capabilities and broad access to key end markets strengthens our evolving global service offering and will allow us to make a positive difference in the lives of more patients, ” he added.
Michael Hendriks, CEO of BModesto said, the company – like Uniphar – is a fast-growing ambitious organisation focused on delivering vital medicines and healthcare services to those who need it most.
“We share common goals which means we have an excellent cultural and strategic fit. Together, we believe we can become a global leader across our area of expertise and make a meaningful impact to patients’ lives,” he added.
© RTÉ 2022. RTÉ.ie is the website of Raidió Teilifís Éireann, Ireland’s National Public Service Media. RTÉ is not responsible for the content of external internet sites.
Images Courtesy of Getty Images.


Shop Sephari